false Q1 --06-30 2025 0001517681 P3Y P5Y 0001517681 2024-07-01 2024-09-30 0001517681 2024-11-14 0001517681 2024-09-30 0001517681 2024-06-30 0001517681 us-gaap:RelatedPartyMember 2024-09-30 0001517681 us-gaap:RelatedPartyMember 2024-06-30 0001517681 us-gaap:NonrelatedPartyMember 2024-09-30 0001517681 us-gaap:NonrelatedPartyMember 2024-06-30 0001517681 PPCB:FormerDirectorMember 2024-09-30 0001517681 PPCB:FormerDirectorMember 2024-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001517681 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001517681 2023-07-01 2023-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001517681 us-gaap:CommonStockMember 2023-06-30 0001517681 PPCB:CommonStockIssuableMember 2023-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001517681 us-gaap:RetainedEarningsMember 2023-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2023-06-30 0001517681 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-06-30 0001517681 us-gaap:CommonStockMember 2024-06-30 0001517681 PPCB:CommonStockIssuableMember 2024-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001517681 us-gaap:RetainedEarningsMember 2024-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2024-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-07-01 2023-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-09-30 0001517681 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001517681 PPCB:CommonStockIssuableMember 2023-07-01 2023-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001517681 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001517681 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-07-01 2024-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001517681 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001517681 PPCB:CommonStockIssuableMember 2024-07-01 2024-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001517681 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001517681 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-09-30 0001517681 us-gaap:CommonStockMember 2023-09-30 0001517681 PPCB:CommonStockIssuableMember 2023-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001517681 us-gaap:RetainedEarningsMember 2023-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001517681 us-gaap:TreasuryStockCommonMember 2023-09-30 0001517681 2023-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001517681 us-gaap:CommonStockMember 2024-09-30 0001517681 PPCB:CommonStockIssuableMember 2024-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001517681 us-gaap:RetainedEarningsMember 2024-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001517681 us-gaap:TreasuryStockCommonMember 2024-09-30 0001517681 2023-05-01 2023-05-01 0001517681 2023-08-31 0001517681 srt:WeightedAverageMember 2024-09-30 0001517681 srt:WeightedAverageMember 2024-06-30 0001517681 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001517681 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001517681 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001517681 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001517681 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001517681 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001517681 PPCB:SeriesAWarrantsMember 2024-07-01 2024-09-30 0001517681 PPCB:SeriesAWarrantsMember 2023-07-01 2023-09-30 0001517681 PPCB:SeriesBWarrantsMember 2024-07-01 2024-09-30 0001517681 PPCB:SeriesBWarrantsMember 2023-07-01 2023-09-30 0001517681 PPCB:SeriesCWarrantsMember 2024-07-01 2024-09-30 0001517681 PPCB:SeriesCWarrantsMember 2023-07-01 2023-09-30 0001517681 PPCB:UnvestedRestrictedStockMember 2024-07-01 2024-09-30 0001517681 PPCB:UnvestedRestrictedStockMember 2023-07-01 2023-09-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2024-07-01 2024-09-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2023-09-30 0001517681 us-gaap:RelatedPartyMember 2023-11-30 0001517681 us-gaap:RelatedPartyMember 2024-05-31 0001517681 us-gaap:RelatedPartyMember 2024-08-31 0001517681 PPCB:LoanAgreementMember 2024-08-01 0001517681 PPCB:LetterAgreementMember 2024-08-01 0001517681 PPCB:LoanAgreementMember 2024-08-01 2024-08-01 0001517681 PPCB:LetterAgreementMember 2023-07-05 0001517681 PPCB:LetterAgreementMember 2023-07-05 2023-07-05 0001517681 2023-07-05 0001517681 us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 2023-07-05 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 2023-07-05 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 PPCB:LetterAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2024-07-01 2024-09-30 0001517681 us-gaap:RelatedPartyMember 2023-07-01 2024-06-30 0001517681 us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2024-07-01 2024-09-30 0001517681 PPCB:LoanAgreementMember 2024-06-30 0001517681 PPCB:LoanAgreementMember 2024-06-01 2024-06-30 0001517681 PPCB:LoanAgreementMember 2024-09-30 0001517681 PPCB:CrownBridgePartnersLLCMember 2024-09-30 0001517681 us-gaap:LoansPayableMember 2023-08-15 0001517681 us-gaap:LoansPayableMember 2023-08-15 2023-08-15 0001517681 us-gaap:LoansPayableMember 2023-08-01 2023-08-31 0001517681 us-gaap:LoansPayableMember 2024-09-30 0001517681 us-gaap:LoansPayableMember 2024-06-30 0001517681 us-gaap:LoansPayableMember 2023-07-01 2024-06-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-05-24 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-05-24 2024-05-24 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:ScenarioForecastMember 2024-11-30 2024-11-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:ScenarioForecastMember 2024-12-30 2024-12-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-10 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-10 2024-06-10 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember us-gaap:LoansPayableMember 2024-12-15 2024-12-15 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:ScenarioForecastMember 2025-01-15 2025-01-15 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-07-01 2024-09-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-09-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-30 0001517681 us-gaap:LoansPayableMember PPCB:PromissoryNoteMember 2024-09-30 0001517681 us-gaap:LoansPayableMember PPCB:PromissoryNoteMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-08-15 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-02-14 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-02-14 2023-02-14 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-12-08 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-12-08 2023-12-08 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember srt:MinimumMember 2023-12-08 2023-12-08 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember srt:MaximumMember 2023-12-08 2023-12-08 0001517681 PPCB:OneFortyFourCapitalMember 2023-06-30 0001517681 PPCB:OneFortyFourCapitalMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2024-07-01 2024-09-30 0001517681 PPCB:OneFortyFourCapitalMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-08-23 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-08-23 2023-08-23 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-10-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-10-12 2023-10-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-04-12 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-04-12 2024-04-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-08-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-08-02 2024-08-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-09-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-09-20 2024-09-20 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-07-01 2024-09-30 0001517681 PPCB:GSCapitalPartnersLLCMember srt:MinimumMember PPCB:SecuritiesPurchaseAgreementMember 2024-09-20 2024-09-20 0001517681 PPCB:GSCapitalPartnersLLCMember srt:MaximumMember PPCB:SecuritiesPurchaseAgreementMember 2024-09-20 2024-09-20 0001517681 2024-09-20 2024-09-20 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-07-01 2024-06-30 0001517681 PPCB:GSCapitalPartnersLLCMember 2024-06-30 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-09-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-07-01 2024-09-30 0001517681 PPCB:GSCapitalPartnersLLCMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-03-05 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MinimumMember 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MaximumMember 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-06-20 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MinimumMember 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MaximumMember 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-06-30 0001517681 PPCB:HundredAndFourLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-07-01 2024-09-30 0001517681 us-gaap:ConvertibleNotesPayableMember 2024-09-30 0001517681 us-gaap:ConvertibleNotesPayableMember 2024-07-01 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2024-07-01 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2023-07-01 2023-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2024-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2023-09-30 0001517681 PPCB:ConvertibleNotesOneMember 2024-07-01 2024-09-30 0001517681 PPCB:ConvertibleNotesOneMember 2023-07-01 2023-09-30 0001517681 2022-05-17 0001517681 2022-05-18 0001517681 2022-09-20 0001517681 2022-09-21 0001517681 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001517681 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001517681 us-gaap:SeriesAPreferredStockMember 2024-06-30 0001517681 us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001517681 us-gaap:ConvertibleDebtMember 2024-09-30 0001517681 PPCB:UnderlyingFinancingAgreementsMember 2024-09-30 0001517681 PPCB:ConsultingAgreementMember 2024-08-12 2024-08-12 0001517681 PPCB:ConsultingAgreementMember 2024-08-12 0001517681 PPCB:ConsultingAgreementMember 2024-07-01 2024-09-30 0001517681 srt:ChiefExecutiveOfficerMember 2019-05-01 2019-05-31 0001517681 PPCB:ChiefScientificOfficerMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-06-30 0001517681 PPCB:UnvestedRestrictedStockUnitsMember 2024-09-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001517681 PPCB:TwoThousandNinteenEquityIncentivePlanMember 2024-09-30 0001517681 2024-08-07 2024-08-07 0001517681 PPCB:SeriesAWarrantsMember 2024-09-30 0001517681 PPCB:SeriesBWarrantsMember 2024-09-30 0001517681 PPCB:SeriesCWarrantsMember 2024-09-30 0001517681 PPCB:CommonStockWarrantsWithNoClassDesignationMember 2024-09-30 0001517681 PPCB:PreReverseStockSplitMember 2024-07-01 2024-09-30 0001517681 PPCB:PreReverseStockSplitMember 2023-07-01 2023-09-30 0001517681 PPCB:PostReverseStockSplitMember 2024-07-01 2024-09-30 0001517681 PPCB:PostReverseStockSplitMember 2023-07-01 2023-09-30 0001517681 PPCB:From2012ThroughThe2014Member 2024-07-01 2024-09-30 0001517681 us-gaap:RoyaltyAgreementTermsMember 2012-06-01 2012-06-30 0001517681 us-gaap:LicenseAgreementTermsMember 2012-06-01 2012-06-30 0001517681 PPCB:OneYearCollaborationAgreementMember 2018-09-13 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember 2018-09-13 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember 2020-10-01 2020-10-01 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentOneMember 2020-11-01 2020-11-30 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentTwoMember 2021-03-01 2021-03-31 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentThreeMember 2021-12-01 2021-12-31 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentFourMember 2022-09-01 2022-09-30 0001517681 PPCB:UniversityOfJaenMember 2020-10-01 2020-10-01 0001517681 2020-10-01 2020-10-01 0001517681 PPCB:UniversityOfJaenMember PPCB:ResearchAgreementMember 2022-07-27 2022-07-27 0001517681 PPCB:InstallmentOneMember PPCB:ResearchAgreementMember 2022-08-01 2022-08-31 0001517681 PPCB:InstallmentTwoMember PPCB:ResearchAgreementMember 2022-09-01 2022-09-30 0001517681 PPCB:InstallmentThreeMember PPCB:ResearchAgreementMember 2022-12-01 2022-12-31 0001517681 PPCB:InstallmentFourMember PPCB:ResearchAgreementMember 2023-03-01 2023-03-31 0001517681 PPCB:InstallmentFiveMember PPCB:ResearchAgreementMember 2023-07-01 2023-07-31 0001517681 2023-07-01 2024-06-30 0001517681 PPCB:UnderwritingAgreementMember PPCB:EFHuttonLLCMember 2024-05-04 2024-05-04 0001517681 PPCB:EquityAndEquityLinkedPlacementsMember 2024-05-04 0001517681 PPCB:DebtPlacementsMember 2024-05-04 0001517681 us-gaap:CommonStockMember 2024-05-04 2024-05-04 0001517681 2024-05-04 0001517681 srt:MaximumMember 2024-05-04 0001517681 PPCB:ConsultantMember 2024-05-04 2024-05-04 0001517681 PPCB:ConsultantMember 2024-05-04 0001517681 PPCB:ConsultantMember PPCB:MergerAcquisitionAgreementMember 2024-05-04 0001517681 PPCB:ConsultantMember PPCB:InitialPayableMember 2024-05-04 0001517681 PPCB:NewThreeYearOperatingLeaseAgreementMember 2022-05-04 0001517681 PPCB:NewThreeYearOperatingLeaseAgreementMember 2022-05-04 2022-05-04 0001517681 us-gaap:AccountingStandardsUpdate201602Member 2022-05-04 0001517681 2022-05-04 2022-05-04 0001517681 PPCB:NorthHorizonPtyLtdMember 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember 2016-05-05 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:NathanielszMember 2016-05-05 0001517681 PPCB:ThreeYearOperatingLeaseAgreementMember PPCB:NorthHorizonPtyLtdMember 2022-05-04 2022-05-04 0001517681 PPCB:NorthHorizonPtyLtdMember 2024-07-01 2024-09-30 0001517681 PPCB:NorthHorizonPtyLtdMember 2023-07-01 2024-06-30 0001517681 2023-11-30 0001517681 2024-05-31 0001517681 2024-08-31 0001517681 PPCB:NathanielszEmploymentAgreementMember 2015-02-25 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember 2022-07-01 2023-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2015-02-25 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2018-03-16 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2018-03-16 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2022-08-01 2022-08-01 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2022-08-01 2022-08-01 0001517681 PPCB:MrsNathanielszMember 2018-02-01 2018-02-01 0001517681 PPCB:JamesNathanielszMember 2016-02-25 2016-02-25 0001517681 PPCB:MrsNathanielszMember 2023-07-01 2024-06-30 0001517681 PPCB:MrsNathanielszMember 2022-07-01 2023-06-30 0001517681 PPCB:MrsNathanielszMember 2024-07-01 2024-09-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2021-08-12 2021-08-12 0001517681 srt:ChiefExecutiveOfficerMember 2020-07-01 2021-06-30 0001517681 srt:ChiefExecutiveOfficerMember PPCB:MrsNathanielszMember 2020-07-01 2021-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2022-08-01 2022-08-01 0001517681 2022-07-01 2023-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2022-07-01 2023-06-30 0001517681 2024-01-01 2024-01-31 0001517681 srt:ChiefExecutiveOfficerMember 2023-07-01 2024-06-30 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:MrNathanielszMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:InitialNathanielszRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:AdditionalNathanielszRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember 2024-07-01 2024-09-30 0001517681 PPCB:EmploymentAgreementMember PPCB:InitialNathanielszRSUsMember 2023-07-01 2024-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2022-10-26 2022-10-26 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2024-07-01 2024-09-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2024-07-01 2024-09-30 0001517681 PPCB:ServicesAgreementMember PPCB:InitialKenyonRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:AdditionalKenyonRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:ServicesAgreementMember 2024-07-01 2024-09-30 0001517681 PPCB:ServicesAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:LenderOneMember 2024-07-01 2024-09-30 0001517681 PPCB:LenderTwoMember 2024-07-01 2024-09-30 0001517681 PPCB:LenderThreeMember 2024-07-01 2024-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderOneMember 2024-07-01 2024-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderTwoMember 2024-07-01 2024-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderThreeMember 2024-07-01 2024-09-30 0001517681 PPCB:LenderOneMember 2023-07-01 2023-09-30 0001517681 PPCB:LenderTwoMember 2023-07-01 2023-09-30 0001517681 PPCB:LenderThreeMember 2023-07-01 2023-09-30 0001517681 PPCB:LenderFourMember 2023-07-01 2023-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderOneMember 2023-07-01 2023-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderTwoMember 2023-07-01 2023-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderThreeMember 2023-07-01 2023-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderFourMember 2023-07-01 2023-09-30 0001517681 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember PPCB:ReceivableMember 2024-07-01 2024-09-30 0001517681 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember PPCB:ReceivableMember 2023-07-01 2024-06-30 0001517681 us-gaap:ConvertibleDebtMember 2024-09-30 0001517681 us-gaap:ConvertibleDebtMember 2024-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember PPCB:NewDerivativeInstrumentsMember srt:MinimumMember 2024-09-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember PPCB:NewDerivativeInstrumentsMember srt:MaximumMember 2024-09-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2024-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember 2024-07-01 2024-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2024-07-01 2024-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2024-07-01 2024-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember srt:MinimumMember 2024-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember srt:MaximumMember 2024-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2024-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2024-09-30 0001517681 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001517681 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001517681 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001517681 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001517681 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001517681 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001517681 us-gaap:DerivativeMember 2024-06-30 0001517681 us-gaap:DerivativeMember 2024-07-01 2024-09-30 0001517681 us-gaap:DerivativeMember 2024-09-30 0001517681 us-gaap:SubsequentEventMember 2024-10-01 2024-10-30 0001517681 us-gaap:SubsequentEventMember 2024-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:AUD iso4217:EUR PPCB:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2024

 

or

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission File Number: 000-54878

 

PROPANC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   33-0662986

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

302, 6 Butler Street

Camberwell, VIC, 3124 Australia

(Address of principal executive offices) (Zip Code)

 

+61-03- 9882-0780

(Registrant’s telephone number, including area code)

 

n/a

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of November 14, 2024, there were 789,899,183 shares of the registrant’s common stock, $0.001 par value per share, issued and outstanding.

 

 

 

 
 

 

PROPANC BIOPHARMA INC.

 

Table of Contents

 

    Page
PART I - FINANCIAL INFORMATION  
     
Item 1. Financial Statements F-1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
Item 3. Quantitative and Qualitative Disclosures About Market Risk 6
Item 4. Controls and Procedures 6
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 8
Item 1A. Risk Factors 8
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
Item 3. Defaults Upon Senior Securities 8
Item 4. Mine Safety Disclosures 8
Item 5. Other Information 8
Item 6. Exhibits 8
  Signatures 9

 

2
 

 

PART I — FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

The following unaudited interim condensed consolidated financial statements of Propanc Biopharma, Inc. are included in this Quarterly Report on Form 10-Q:

 

INDEX TO FINANCIAL STATEMENTS

 

  Page
Condensed Consolidated Balance Sheets at September 30, 2024 (unaudited) and June 30, 2024 F-2
   
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended September 30, 2024 and 2023 (unaudited) F-3
   
Condensed Consolidated Statements of Changes in Stockholders’ Deficit for each of the three months in the periods ended September 30, 2024 and 2023 (unaudited) F-4
   
Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2024 and 2023 (unaudited) F-5
   
Notes to the Condensed Consolidated Financial Statements (unaudited) F-6

 

F-1
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30, 2024   June 30, 2024 
   (Unaudited)     
ASSETS          
           
CURRENT ASSETS:          
Cash  $9,268   $21,085 
GST tax receivable   3,309    2,950 
Prepaid expenses and other current assets   8,957    1,406 
           
TOTAL CURRENT ASSETS   21,534    25,441 
           
Deferred offering costs   27,117    27,117 
Security deposit - related party   2,081    2,008 
Operating lease right-of-use assets, net - related party   12,912    17,799 
           
TOTAL ASSETS  $63,644   $72,365 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable  $1,238,589   $1,213,335 
Accrued expenses and other payables   875,199    792,190 
Accrued interest   111,652    94,612 
Loans payable   145,091    145,091 
Loans payable - related parties   227,328    71,629 
Notes payable, net of discount   213,109    204,694 
Convertible notes, net of discounts and including put premiums   381,789    399,325 
Operating lease liability - related party, current portion   14,185    19,362 
Embedded conversion option liabilities   134,234    133,886 
Due to former director - related party   30,840    29,759 
Loan from former director - related party   51,326    49,528 
Employee benefit liability   677,902    639,371 
           
TOTAL CURRENT LIABILITIES   4,101,244    3,792,782 
           
NON-CURRENT LIABILITIES:          
Loan payable - long-term - related party, net of discount   70,485    58,642 
           
TOTAL NON-CURRENT LIABILITIES   70,485    58,642 
           
TOTAL LIABILITIES  $4,171,729   $3,851,424 
           
Commitments and Contingencies (See Note 8)   -    - 
           
STOCKHOLDERS’ DEFICIT:          
Preferred stock, 1,500,005 shares authorized, $0.01 par value:          
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of September 30, 2024 and June 30, 2024   -    - 
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 688,022,017 and 478,802,488 shares issued and outstanding as of September 30, 2024 and June 30, 2024, respectively   688,022    478,802 
Additional paid-in capital   61,132,262    61,217,255 
Accumulated other comprehensive income   1,170,638    1,269,581 
Accumulated deficit   (67,052,530)   (66,698,220)
Treasury stock ($0.001 share)   (46,477)   (46,477)
           
TOTAL STOCKHOLDERS’ DEFICIT   (4,108,085)   (3,779,059)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $63,644   $72,365 

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

 

   2024   2023 
   For the three months ended September 30, 
   2024   2023 
         
REVENUE          
Revenue  $-   $- 
           
OPERATING EXPENSES          
Administration expenses   220,759    393,828 
Occupancy expenses - related party   8,317    7,149 
Research and development   61,714    16,242 
TOTAL OPERATING EXPENSES   290,790    417,219 
           
LOSS FROM OPERATIONS   (290,790)   (417,219)
           
OTHER INCOME (EXPENSE)          
Interest expense   (86,230)   (178,234)
Interest income   1    17 
Derivative expense   (27,182)   (77,721)
Change in fair value of derivative liabilities   52,787    303,929 
Gain (loss) on extinguishment of debt, net   (11,319)   34,310 
Foreign currency transaction gain (loss)   8,423    (15,948)
TOTAL OTHER INCOME (EXPENSE), NET   (63,520)   66,353 
           
LOSS BEFORE TAXES   (354,310)   (350,866)
           
Tax benefit   -    - 
           
NET LOSS  $(354,310)  $(350,866)
           
Deemed Dividend   -    (142,575)
           
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  $(354,310)  $(493,441)
           
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS  $(0.00)  $(0.04)
           
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING   590,937,498    10,989,681 
           
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  $(354,310)  $(493,441)
           
OTHER COMPREHENSIVE INCOME (LOSS)          
Unrealized foreign currency translation gain (loss)   (98,943)   73,674 
           
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)   (98,943)   73,674 
           
TOTAL COMPREHENSIVE LOSS  $(453,253)  $(419,767)

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Unaudited)

 

                                                     
   Preferred Stock           Common Stock           Accumulated        
   Series A   Series B   Common Stock   Issuable   Additional      

Other

       Total 
   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   Paid-in Capital   Accumulated Deficit  

Comprehensive

Income

   Treasury Stock  

Stockholders’

Deficit

 
                                                     
Balance at June 30, 2023   -   $-    1   $-    6,031,250   $6,031    1,621,653   $1,621   $60,311,502   $(64,684,732)  $1,294,876   $(46,477)  $(3,117,179)
                                                                  
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest   -    -    -    -    4,898,307    4,899    626,229    626    223,665    -    -    -    229,190 
                                                                  
Issuance of common stock for alternate cashless exercise of warrants   -    -    -    -    2,282,000    2,282    -    -    (2,282)   -    -    -    - 
                                                                  
Issuance of common stock for issuable shares   -    -    -    -    1,621,653    1,621    (1,621,653)   (1,621)   -    -    -    -    - 
                                                                  
Reclassification of put premium upon debt conversion   -    -    -    -    -    -    -    -    34,838    -    -    -    34,838 
                                                                  
Relative fair value of warrant granted in connection with a loan payable - related party   -    -    -    -    -    -    -    -    141,084    -    -    -    141,084 
                                                                  
Foreign currency translation gain   -    -    -    -    -    -    -    -    -    -    73,674    -    73,674 
                                                                  
Deemed dividend upon alternate cashless exercise of warrants   -    -    -    -    -    -    -    -    142,575    (142,575)   -    -    - 
                                                                  
Net loss for the three months ended September 30, 2023   -    -    -    -    -    -    -    -    -    (350,866)   -    -    (350,866)
                                                                  
Balance at September 30, 2023   -   $-    1   $-    14,833,210   $14,833   $626,229   $626   $60,851,382   $(65,178,173)  $1,368,550   $(46,477)  $(2,989,259)

 

   Preferred Stock           Common Stock           Accumulated         
   Series A   Series B   Common Stock   Issuable   Additional       Other       Total 
   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value  

Paid-in

Capital

  

Accumulated

Deficit

  

Comprehensive

Income

  

Treasury

Stock

  

Stockholders’

Deficit

 
                                                     
Balance at June 30, 2024   -   $-    1   $-    478,802,488   $478,802    -   $-   $61,217,255   $(66,698,220)  $1,269,581   $(46,477)  $(3,779,059)
                                                                  
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest   -    -    -    -    194,219,529    194,220    -    -    (94,329)   -    -    -    99,891 
                                                                  
Issuance of common stock for services   -    -    -    -    15,000,000    15,000    -    -    -    -    -    -    15,000 
                                                                  
Reclassification of put premium upon debt conversion   -    -    -    -    -    -    -    -    9,336    -    -    -    9,336 
                                                                  
Foreign currency translation loss   -    -    -    -    -    -    -    -    -    -    (98,943)   -    (98,943)
                                                                  
Net loss for the three months ended September 30, 2024   -    -    -    -    -    -    -    -    -    (354,310)   -    -    (354,310)
                                                                  
Balance at September 30, 2024   -   $-    1   $-    688,022,017   $688,022    -   $-   $61,132,262   $(67,052,530)  $1,170,638   $(46,477)  $(4,108,085)

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2024   2023 
   For the three months ended
September 30,
 
   2024   2023 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(354,310)  $(350,866)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:          
Issuance of common stock for services   7,500    - 
Foreign currency transaction loss (gain)   (8,423)   15,948 
Depreciation expense   -    134 
Amortization of debt discounts   56,983    69,457 
Amortization of right-of-use assets   5,534    5,128 
Change in fair value of derivative liabilities   (52,787)   (303,929)
Derivative expense   27,182    77,721 
Loss (gain) on extinguishment of debt, net   11,319    (34,310)
Non-cash interest expense   2,548    1,437 
Accretion of put premium   -    88,846 
Changes in Assets and Liabilities:          
GST receivable   (251)   132 
Prepaid expenses and other assets   -    (14,468)
Refundable advance deposit   -    (116,169)
Accounts payable   (18,797)   148,834 
Employee benefit liability   15,317    12,275 
Accrued expenses and other payables   54,457    55,693 
Accrued interest   24,093    15,712 
Operating lease liability   (5,880)   (5,032)
NET CASH USED IN OPERATING ACTIVITIES   (235,515)   (333,457)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from convertible promissory notes, net of original issue discounts and issue costs   60,000    220,000 
Repayment of convertible note   -    (142,909)
Proceeds from note payable   -    120,000 
Proceeds from loans payable - related parties   155,699    153,256 
NET CASH PROVIDED BY FINANCING ACTIVITIES   215,699    350,347 
           
Effect of exchange rate changes on cash   7,999    (20,312)
           
NET DECREASE IN CASH   (11,817)   (3,422)
           
CASH AT BEGINNING OF PERIOD   21,085    10,047 
           
CASH AT END OF PERIOD  $9,268   $6,625 
           
Supplemental Disclosure of Cash Flow Information          
          
Cash paid during the year:          
Interest  $2,606   $2,713 
Income Tax  $-   $- 
           
Supplemental Disclosure of Non-Cash Investing and Financing Activities          
           
Reduction of put premium related to conversions of convertible notes  $9,336   $34,838 
Conversion of convertible notes and accrued interest to common stock  $51,978   $114,131 
Debt discounts related to derivative liability  $60,000   $70,000 
Relative fair value of warrant granted in connection with a loan payable - related party  $-   $141,084 
Deemed dividend upon alternate cashless exercise of warrants  $-   $142,575 
Issuance of common stock for prepaid service  $7,500   $- 

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-5
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES

 

Nature of Operations

 

Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development.

 

The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company.

 

On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2024, there has been no activity within this entity.

 

Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better.

 

In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid  tumors, covering the lead product candidate PRP.

 

On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) Reverse Stock Split (the “Reverse Stock Split”), effective as of May 1, 2023. Proportional adjustments for the Reverse Stock Split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements to reflect the Reverse Stock Split.

 

The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.

 

Basis of Presentation

 

The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2024 and 2023 and cash flows for the three months ended September 30, 2024 and 2023 and our consolidated financial position at September 30, 2024 have been made. The Company’s results of operations for the three months ended September 30, 2024 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2025.

 

Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2024. The June 30, 2024 balance sheet is derived from those statements.

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2024 and still remains inactive.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.

 

F-6
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Foreign Currency Translation and Other Comprehensive Income (Loss)

 

The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date.

 

Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).

 

Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of September 30, 2024 and 2023, the Company recognized a cumulative exchange gain (loss) of approximately $677,000 and $669,000, respectively, on intercompany loans made by the parent to the subsidiary that have not been repaid as of September 30, 2024, which is included as a component of accumulated other comprehensive income on the accompanying condensed consolidated balance sheets.

 

As of September 30, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows:

 

   September 30, 2024   June 30, 2024 
Exchange rate on balance sheet dates          
USD : AUD exchange rate   0.6936    0.6693 
Average exchange rate for the period          
USD : AUD exchange rate   0.6668    0.6557 

 

The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2024 was as follows:

 

   Foreign
Currency Items:
 
Balance, June 30, 2024  $1,269,581 
Unrealized foreign currency translation loss   (98,943)
Ending balance, September 30, 2024  $1,170,638 

 

Fair Value of Financial Instruments and Fair Value Measurements

 

The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same.

 

The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost).

 

The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

 

Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

 

F-7
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of September 30, 2024 or June 30, 2024.

 

Refundable Advance Deposit

 

In August 2023, the Company paid a refundable advance deposit of $120,958 which consisted primarily of a deposit paid to a potential lender to be used as payment for a loan insurance premium related to a future loan transaction with the Company. In the event, the future loan transaction does not close, the potential lender shall return the refundable advance deposit. During fiscal year 2024, the Company recorded an allowance for the recoverability of this refundable advance deposit of $120,958.

 

Deferred Offering Costs

 

The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of September 30, 2024 and June 30, 2024, the Company had recorded $27,117 in deferred offering costs for both periods.

 

Property and Equipment

 

Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value.

 

The estimated useful lives are as follows:

 

Machinery and equipment - 5 years
Furniture - 7 years

 

Patents

 

Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.

 

Impairment of Long-Lived Assets

 

In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

 

Employee Benefit/Liability

 

Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.

 

F-8
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Australian Goods and Services Tax (“GST”)

 

Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.

 

Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

 

As of September 30, 2024 and June 30, 2024, the Company was owed $3,309 and $2,950, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates.

 

Derivative Instruments

 

ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”), establishes accounting and reporting standards for derivative instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt, the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any discounts and records a net gain or loss on debt extinguishment.

 

Convertible Notes With Variable Conversion Options

 

The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $0.001 per share (“common stock”) at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “Distinguishing Liabilities from Equity” and measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion and records the put premium as interest expense.

 

Income Taxes

 

The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “Accounting for Income Taxes,” when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

 

The Company follows ASC 740, Sections 25 through 60, “Accounting for Uncertainty in Income Taxes.” These sections provide detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of ASC 740 and in subsequent periods.

 

Research and Development Costs and Tax Credits

 

In accordance with ASC 730-10, “Research and Development-Overall,” research and development costs are expensed when incurred. Total research and development costs for the three months ended September 30, 2024 and 2023 were $61,714 and $16,242, respectively.

 

The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt.

 

Stock Based Compensation

 

The Company records stock-based compensation in accordance with ASC 718, “Stock Compensation”. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

 

The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.

 

Revenue Recognition

 

The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.

 

F-9
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Legal Expenses

 

All legal costs for litigation are charged to expense as incurred.

 

Leases

 

The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.

 

Basic and Diluted Net Loss Per Common Share

 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. The Company’s CEO holds Series B Preferred Stock that, when combined, confers upon him a majority vote, including regarding authorization of additional common shares and/or the authorization of a reverse split the stock as considered necessary. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.

 

   September 30, 2024   September 30, 2023 
   (Unaudited)   (Unaudited) 
Stock Options   0.06    0.06 
Stock Warrants with no designations   15,003,306    15,003,306 
Series A Warrants as if converted at alternate cashless exercise price   1,990,353,990    1,994,343,990 
Series B Warrants   16    16 
Series C Warrants as if converted at alternate cashless exercise price *   9,175,999,954    9,175,999,954 
Unvested restricted stock   0.06    0.06 
Convertible Debt   1,823,504,274    210,849,945 
Total   13,004,861,540.12    11,396,197,211.12 

 

*Only convertible ratably upon exercise of Series B Warrants

 

Recent Accounting Pronouncements

 

We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

F-10
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

NOTE 2 – GOING CONCERN

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the three months ended September 30, 2024, the Company had no revenues, had a net loss of $354,310, and had net cash used in operations of $235,515. Additionally, As of September 30, 2024, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $4,079,710, $4,108,085, and $67,052,530, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.

 

The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

 

Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

 

NOTE 3 – PROPERTY AND EQUIPMENT

 

Property and equipment consist of the following As of September 30, 2024 and June 30, 2024.

 

   September 30, 2024   June 30, 2024 
   (Unaudited)     
Office equipment at cost  $26,471   $25,543 
Less: Accumulated depreciation   (26,471)   (25,543)
           
Total property, plant, and equipment  $-   $- 

 

Depreciation expense for the three months ended September 30, 2024 and 2023 were $0 and $134, respectively.

 

NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY

 

Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at September 30, 2024 and June 30, 2024 were $30,840 and $29,759, respectively. The Company plans to repay the advances as its cash resources allow (see Note 9).

 

NOTE 5 – LOANS

 

Loan from Former Director - Related Party

 

Loan from the Company’s former director at September 30, 2024 and June 30, 2024 were $51,326 and $49,528, respectively. The loan bears no interest and is payable on demand. The Company did not repay any amount on this loan during the three months ended September 30, 2024 and 2023, respectively (see Note 9).

 

Loans payable - Related Parties

 

Between November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $71,629. Additionally, in August 2024, the same affiliated institutional investor loaned the Company an amount of 85,000 AUD ($57,639 USD). These loans bear no interest and are payable on demand.

 

Effective August 1, 2024, the Company entered into and closed a loan agreement (the “Loan”) with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $150,000 AUD ($98,060 USD). The Company used the net proceeds for general working capital purposes. The maturity date of the Loan is November 1, 2024, or sooner at the discretion of the Company, and the Loan bears an interest rate of 12% per annum and default interest rate of 18% per annum. The Company has the right to prepay in full at any time with no prepayment penalty. By mutual consent the amount can be repaid via the issuance of common stock of the Company (upon uplisting on NASDAQ) and the strike price shall be at a 35% discount to lowest daily balance of the five preceding trading days. As of the date of filing this report, such Loan is past due and currently in default.

 

The loans payable – related parties amounted to $227,328 and $71,629 as of September 30, 2024 and June 30, 2024, respectively.

 

F-11
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Loan payable -long-term- Related Party

 

On July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $230,000 AUD ($153,256 USD). Pursuant to such agreement, the term of such loan is three (3) years, ending on July 5, 2026, with an interest rate of 10% to be paid monthly in arrears. In connection with such loan, the Company issued 15,000,000 warrants to purchase common stock to such investor immediately exercisable at an initial exercise price of $0.01 per share (subject to certain adjustments such as stock dividend, stock splits, subsequent right offering and pro-rata distribution) with an expiry date of July 5, 2026. The Company accounted for the 15,000,000 warrants issued with this loan payable as debt discount by using the relative fair value method. The total debt discount which is equivalent to the relative fair value of the warrants of $141,084 was based on a fair value determination using a Black-Scholes model with the following assumptions: stock price at valuation date of $0.119 based on the closing price of common stock at date of grant, exercise price of $0.01, dividend yield of zero, expected term of 3.00, a risk-free rate of 4.59%, and expected volatility of 268%. The debt discount shall be amortized over the term of this loan. A portion of the proceeds of such loan were used to repay an outstanding balance of approximately $143,000 due on a convertible note held by a third-party investor and which had been in default.

 

Accrued interest from this loan amounted to $15,158 as of June 30, 2024. Amortization of debt discount from this loan for fiscal year 2024 was $46,470. The total principal outstanding under this loan was $153,256 and remaining unamortized debt discount of $94,614 as of June 30, 2024 as reflected in the accompanying condensed consolidated balance sheet as loan payable – long-term – related party, net of discount of $58,642.

 

Accrued interest from this loan amounted to $19,020 as of September 30, 2024. Amortization of debt discount for the three months ended September 30, 2024 was $11,843. The total principal outstanding under this loan was $153,256 and remaining debt discount of $82,771 as of September 30, 2024 as reflected in the accompanying condensed consolidated balance sheet as loan payable – long-term – related party, net of discount of $70,485.

 

Loan Payable

 

Crown Bridge Securities Purchase Agreement

 

Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $65,280 as of June 30, 2024. The maturity date of the Crown Bridge Note was October 3, 2020 and is currently past due. The Crown Bridge Note bore interest at a default interest rate of 15% per annum. In August 2022, the SEC filed a complaint against Crown Bridge due to its violation of Section 15(a)(1) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Crown Bridge agreed to surrender all conversion rights in its currently held convertible notes, including the Crown Bridge Note. Consequently, during fiscal year 2023, the Company reclassified the remaining principal balance of $65,280 from a convertible note into a loan payable which is the principal balance at September 30, 2024 and June 30, 2024. Additionally, the Company recorded the remaining put premium of $43,520 into gain on extinguishment of debt during fiscal year 2023. The total accrued interest from this loan amounted to $48,009 and $45,541 as of September 30, 2024 and June 30, 2024, respectively.

 

Loans Payable - others

 

In June 2024, the Company entered into loan agreements with two investors who loaned the Company an aggregate of $120,000 AUD ($79,811 USD). The maturity dates of these loans are both in June 2025. These loans bear interest at a rate of 12% per annum. As of September 30, 2024 and June 30, 2024, the total balance of these loans amounted to $79,811 for both periods and accrued interest of $3,079 and $665, respectively.

 

The aggregate principal outstanding on the above loans was $145,091 as of September 30, 2024 and June 30, 2024.

 

Loan in default

 

The Crown Bridge Note is currently past due and in default, consisting of $65,280 principal and $48,009 accrued interest, which includes interest accruing at the default interest rate at 15%.

 

NOTE 6 – NOTES PAYABLE AND CONVERTIBLE NOTES

 

Promissory Note

 

On August 15, 2023, the Company issued to an institutional investor (the “August 2023 Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000, matured on November 15, 2023 and accrued interest at a rate of 10% per annum, and was increased to 18% due to the event of a default. The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment. The Promissory Note contains certain customary events of default set forth in the Promissory Note, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Promissory Note. On May 7, 2024, the August 2023 Lender notified the Company that the 130% default repayment plus interest will be waived and shall extend the maturity of the Promissory Note to September 30, 2024. As of the date of filing this report, such Promissory Note is past due and currently in default.

 

F-12
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Accrued interest from this note amounted to $18,863 and $15,536 as of September 30, 2024 and June 30, 2024, respectively. Amortization of debt discount from the promissory note for fiscal year 2024 was $12,000. The total principal outstanding under this note was $132,000 and remaining debt discount of $0 as of September 30, 2024 and June 30, 2024 as reflected in the accompanying condensed consolidated balance sheet as note payable of $132,000.

 

1800 Diagonal Lending Promissory Notes

 

On May 24, 2024, the Company entered into a 15% promissory note in the amount of $49,200 less original issue discount of $8,200 and legal and financing costs of $6,000 for net proceeds of $35,000 with 1800 Diagonal Lending, LLC. The principal and accrued interest is payable on or before March 30, 2025. Any amount of principal or interest on this note which is not paid when due shall bear interest at the rate of twenty two percent (22%) per annum from the due date thereof until the same is paid. Accrued, unpaid interest and outstanding principal, subject to adjustment, shall be paid on November 30, 2024 in the amount of $28,290 and 4 payments each in the amount of $7,072.50 (a total payback to the Holder of $56,580). The first payment of $7,072.50 shall be due on December 30, 2024 with 3 subsequent payments each month thereafter. The Company shall have a five (5) day grace period with respect to each payment.

 

On June 10, 2024, the Company entered into a 15% promissory note in the amount of $49,200 less original issue discount of $8,200 and legal and financing costs of $6,000 for net proceeds of $35,000 with 1800 Diagonal Lending, LLC. The principal and accrued interest is payable on or before April 15, 2025. Any amount of principal or interest on this note which is not paid when due shall bear interest at the rate of twenty two percent (22%) per annum from the due date thereof until the same is paid. Accrued, unpaid interest and outstanding principal, subject to adjustment, shall be paid on December 15, 2024 in the amount of $28,290 and 4 payments each in the amount of $7,072.50 (a total payback to the Holder of $56,580). The first payment of $7,072.50 shall be due on January 15, 2025 with 3 subsequent payments each month thereafter. The Company shall have a five (5) day grace period with respect to each payment.

 

The Company has right to accelerate payments or prepay in full at any time with no prepayment penalty. At any time following an event of default, the noteholder shall have the right, to convert all or any part of the outstanding and unpaid amount of these notes into shares of common stock. The conversion price of the above notes shall mean 65% multiplied by the lowest trading price for the common stock during the 10 trading days prior to the conversion date (representing a discount rate of 35%) subject to a 4.99% beneficial ownership limitations. Upon the occurrence of any event of defaults, these notes shall be immediately due and payable in an amount equal to 150% default percentage multiplied by the sum of the outstanding principal balances plus accrued interest and default interest.

 

As of September 30, 2024 and June 30, 2024 the total balance of these 1800 Diagonal Lending promissory notes amounted to $98,400 for both periods and accrued interest of $4,913 and $1,193, respectively.

 

The total balance of the above three promissory notes, net of unamortized discount of $17,291 was $213,109 at September 30, 2024. The total balance of the above three promissory notes, net of unamortized discount of $25,706 was $204,694 at June 30, 2024.

 

Convertible Notes

 

The Company’s convertible notes outstanding at September 30, 2024 and June 30, 2024 were as follows:

 

  

September 30, 2024

(Unaudited)

   June 30, 2024 
Convertible notes and debenture  $334,625   $313,550 
Unamortized discounts   (68,129)   (38,854)
Premium, net   115,293    124,629 
Convertible notes, net  $381,789   $399,325 

 

ONE44 Capital Securities Purchase Agreements

 

August 15, 2022 Securities Purchase Agreement

 

On August 15, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $110,000, such principal and the interest thereon were convertible into shares of the common stock at the option of ONE44 any time after the six-month anniversary of the August 15, 2022 ONE44 Note. The transaction contemplated by such purchase agreement closed on August 16, 2022. The August 15, 2022 One44 Note contained an original issue discount amount of $10,000. Pursuant to the terms of such purchase agreement, the Company paid $5,500 for ONE44’s legal fees. The Company used the net proceeds from the August 15, 2022 ONE44 Note for general working capital purposes. The maturity date of the August 15, 2022 One44 Note was August 15, 2023. The August 15, 2022 ONE44 Note bore interest at a rate of 10% per annum, which was payable in shares of common stock, but was not payable until the maturity date or upon acceleration or by prepayment of such note. The August 15, 2022 ONE44 Note was fully converted in fiscal year 2024.

 

February 14, 2023 Securities Purchase Agreement

 

On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $111,111, such principal and the interest thereon were convertible into shares of the common stock at the option of ONE44 any time after the six-month anniversary of the February 14, 2023 ONE44 Note. The transaction contemplated by such purchase agreement closed on February 14, 2023. The February 14, 2023 One44 Note contained an original issue discount amount of $11,111. Pursuant to the terms of such purchase agreement, the Company paid $5,500 for ONE44’s legal fees. The Company used the net proceeds from the February 14, 2023 ONE44 Note for general working capital purposes. The maturity date of the February 14, 2023 One44 Note was February 14, 2024. The February 14, 2023 ONE44 Note bore interest at a rate of 10% per annum, which interest was payable in shares of common stock, but was not payable until the maturity date or upon acceleration or by prepayment of such note. The February 14, 2023 One44 Note was fully converted in fiscal year 2024.

 

F-13
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

December 8, 2023 Securities Purchase Agreement

 

On December 8, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “December 8, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $150,000, such principal and the interest thereon are convertible into shares of the common stock at the option of ONE44 any time after the six-month anniversary of the December 8, 2023 ONE44 Note. The transaction contemplated by such purchase agreement closed on December 8, 2023. The December 8, 2023 One44 Note contains an original issue discount amount of $15,000. Pursuant to the terms of such purchase agreement, the Company paid $7,500 for ONE44’s legal fees. The Company used the net proceeds from the December 8, 2023 ONE44 Note for general working capital purposes. The maturity date of the December 8, 2023 One44 Note is December 8, 2024. The December 8, 2023 ONE44 Note bears interest at a rate of 10% per annum, which interest is payable in shares of common stock, but is not payable until the maturity date or upon acceleration or by prepayment of such note.

 

The following terms shall apply to all of the above ONE44 note:

 

During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120% to 135% as defined in the relevant note. After this initial 180-day period, the Company does not have a right to prepay such note.

 

The conversion price for the above ONE44 notes ranges from 60% to 65% (representing a 35% to 40% discount) of the market price of the common stock, which is based on the lowest closing bid prices of the common stock between ten and fifteen trading days immediately prior to the delivery of a notice of conversion. Notwithstanding the foregoing, such notes are subject to 4.99% beneficial ownership limitations. All of the above ONE44 notes are treated as stock settled debt under ASC 480 and accordingly the Company recorded a total debt premium of $133,305 during the year ended June 30, 2023 and recorded a total debt premium of $100,000 was recorded during the year ended June 30, 2024.

 

The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. In the event that the Company fails to deliver to ONE44 shares of common stock issuable upon conversion of principal or interest under a ONE44 note, it will incur a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company. This penalty increases to $500 per day beginning on the 10th day. In the event that the Company loses the bid price of its common stock on OTC, such ONE44 note does not incur penalty and instead the outstanding principal amount increases by 20%.

 

The total principal amount outstanding under the above ONE44 financing agreements was $119,300 and accrued interest was $6,726 as of June 30, 2024 following conversion of $148,811 of the principal balance and $9,909 accrued interest during the year ended June 30, 2024. Accordingly, $98,311 of the put premium was released to additional paid in capital in respect to the ONE44 financing agreements during the year ended June 30, 2024 following conversion of the principal balance.

 

The total principal amount outstanding under the above ONE44 financing agreements was $105,800 and accrued interest was $8,645 as of September 30, 2024 following conversion of $13,500 of the principal balance and $841 accrued interest during the three months ended September 30, 2024. Accordingly, $9,000 of the put premium was released to additional paid in capital in respect to the ONE44 financing agreements during the three months ended September 30, 2024 following conversion of the principal balance.

 

GS Capital Partners Securities Purchase Agreements

 

August 23, 2023 Securities Purchase Agreement

 

On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $77,500, such principal and the interest thereon are convertible into shares of the Company’s common stock at the option of GS Capital. The GS Capital Note contains a $5,000 original issue discount. Pursuant to the terms of the GS Purchase Agreement, the Company paid GS Capital’s legal fees of $2,500. The Company used the net proceeds from the GS Capital Note for general working capital purposes.

 

The maturity date of the GS Capital Note was February 23, 2024 and is currently in default. The GS Capital Note bore an interest at a rate of 8% per annum and was increased to 24% due to the event of a default, which interest may be paid by the Company to GS Capital in shares of common stock but shall not be payable until the GS Capital Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment. The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share, provided that the fixed price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.

 

F-14
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

October 12, 2023 Securities Purchase Agreement

 

On October 12, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $61,000, such principal and the interest thereon are convertible into shares of the Company’s common stock at the option of GS Capital. The GS Capital Note contains a $3,500 original issue discount. Pursuant to the terms of the GS Purchase Agreement, the Company paid GS Capital’s legal fees of $2,500. The Company intends to use the net proceeds from the GS Capital Note for general working capital purposes.

 

The maturity date of the GS Capital Note was April 12, 2024 and is currently in default. The GS Capital Note bore interest at a rate of 8% per annum and was increased to 24% due to the event of a default, which interest may be paid by the Company to GS Capital in shares of common stock but shall not be payable until the GS Capital Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment. The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share, provided that the fixed price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.

 

April 12, 2024 Securities Purchase Agreement

 

On April 12, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $27,500, such principal and the interest thereon are convertible into shares of the Company’s common stock at the option of GS Capital. The GS Capital Note contains a $2,500 original issue discount. The Company intends to use the net proceeds from the GS Capital Note for general working capital purposes.

 

The maturity date of the GS Capital Note is October 12, 2024. The GS Capital Note shall bear interest at a rate of 8% per annum, which interest may be paid by the Company to GS Capital in shares of common stock but shall not be payable until the GS Capital Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment. The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share, provided that the fixed price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default.

 

August 2, 2024 Securities Purchase Agreement

 

On August 2, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $33,000, such principal and the interest thereon are convertible into shares of the Company’s common stock at the option of GS Capital. The GS Capital Note contains a $3,000 original issue discount. The Company used the net proceeds from the GS Capital Note for general working capital purposes.

 

The maturity date of the GS Capital Note is February 2, 2025. The GS Capital Note shall bear interest at a rate of 8% per annum, which interest may be paid by the Company to GS Capital in shares of common stock but shall not be payable until the GS Capital Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment. The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share, provided that the fixed price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.

 

September 20, 2024 Securities Purchase Agreement

 

On September 20, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $33,000, such principal and the interest thereon are convertible into shares of the Company’s common stock at the option of GS Capital. The GS Capital Note contains a $3,000 original issue discount. The Company used the net proceeds from the GS Capital Note for general working capital purposes.

 

The maturity date of the GS Capital Note is March 20, 2025. The GS Capital Note shall bear interest at a rate of 8% per annum, which interest may be paid by the Company to GS Capital in shares of common stock but shall not be payable until the GS Capital Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment. The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0003 per share, provided that the fixed price will be reduced to $0.0001 per share in the event that the market price of the Common Stock trades below $0.0003 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.

 

F-15
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

The following terms shall apply to all of the above GS Capital notes:

 

Pursuant to the above GS Capital notes, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note.

 

Additionally, the conversion prices of the above GS Capital notes will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. The effective conversion price of the outstanding GS Capital notes are 60% (representing a 40% discount) of the market price, which means the lowest closing bid prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion.

 

The above GS Capital notes were bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value.

 

During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110% to 125% of the principal amount and interest of such note. After this initial 180-day period, the Company does not have a right to prepay such notes.

 

Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. In the event that the Company fails to deliver to GS Capital shares of common stock issuable upon conversion of principal or interest under the above GS Capital notes, the penalty becomes $250 per day for each day that the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company. This penalty increases to $500 per day beginning on the 10th day. In the event that the Company loses the bid price of its common stock on OTC, such GS Capital note does not incur penalty and instead the outstanding principal amount increases by 20%.

 

The total principal outstanding and accrued interest under the above GS Capital notes were $110,500 and $8,364, respectively, as of June 30, 2024, following conversion of $130,800 of the principal balance, $8,700 accrued interest (including $1,254 at default interest rate) and $3,832 conversion fees during the year ended June 30, 2024. During fiscal year 2024, an aggregate total of $110,500 of the above GS Capital notes were bifurcated with the embedded conversion option which were recorded as derivative liabilities at fair value as of June 30, 2024 (see Note 11).

 

The total principal outstanding and accrued interest under the above GS Capital notes were $145,700 and $7,902, respectively, as of September 30, 2024, following conversion of $30,800 of the principal balance and $2,212 accrued interest during the three months ended September 30, 2024. During the three months ended September 30, 2024, an aggregate total of $66,000 of the above GS Capital notes were bifurcated with the embedded conversion option which were recorded as derivative liabilities at fair value (see Note 11).

 

One GS Capital note with principal amount of $52,200 is currently in default and accrues at a default interest rate of 24% per annum.

 

104 LLC Securities Purchase Agreement

 

March 5, 2024 Securities Purchase Agreement

 

Effective March 5, 2024, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) with 104 LLC (“104”), pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000, for a purchase price of $46,875, after an original issue discount of $3,125. The Company paid legal and financing costs of $7,500. The Company used the net proceeds therefrom for general working capital purposes. The maturity date of the note is March 1, 2025 and the note bears interest at a rate of eight percent (8%) per annum, which may be increased to sixteen percent (16%) in the event of a default.

 

June 20, 2024 Securities Purchase Agreement

 

Effective June 20, 2024, Company entered into and closed a securities purchase agreement with 104 LLC, pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $33,750, for a purchase price of $30,375, after an original issue discount of $3,375. The Company paid legal and financing costs of $5,200. The Company used the net proceeds therefrom for general working capital purposes. The maturity date of the note is June 20, 2025 and the note bears interest at a rate of eight percent (8%) per annum, which may be increased to sixteen percent (16%) in the event of a default.

 

The principal and interest on the notes are convertible into shares of common stock of the Company at the option of 104 at any time following the issuance date of the notes (the “Conversion Shares”) at a price per share equal to 65% of the lowest closing trade price of the common stock during the ten (10) trading days prior to conversion (representing a discount of 35%). Notwithstanding the foregoing, such conversions are subject to a 4.99% beneficial ownership limitation and adjustments for mergers, consolidations, reorganizations and similar events set forth in the notes, other than a transfer or sale of all or substantially all Company assets. Pursuant to the notes, the Company is required to maintain an initial reserve of at least 500% of the number of conversion shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the notes. The above 104 notes treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $45,096 was recorded as a put premium during the year ended June 30, 2024.

 

F-16
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

During the first 60 days following the date of the notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes.

 

The 104 notes contain certain events of default, including failure to pay principal and interest when due, failure to timely issue the conversion shares, failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, failure to comply with its reporting requirements with the U.S. Securities and Exchange Commission, a breach of certain covenants in the purchase agreement, default by the Company under any other note issued to the Investor, as well as certain customary events of default set forth in the notes, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, and liquidation. Upon an event of default, the notes will become immediately due and payable by the Company.

 

The total principal amount outstanding under the above 104 financing agreements was $83,750 and accrued interest was $1,429 as of June 30, 2024. The total principal outstanding and accrued interest under the above 104 financing agreements were $83,125 and $0, respectively, as of September 30, 2024, following conversion of $625 of the principal balance and $4,000 accrued interest during the three months ended September 30, 2024.

 

Outstanding convertible notes in default

 

Outstanding convertible notes for total principal amount of $83,000 with maturity dates between February 23, 2024 and April 12, 2024 are currently in default as of the date of this filing.

 

Amortization of debt discounts

 

The Company recorded $66,000 and $92,500 of debt discounts related to the above note issuances during the three months ended September 30, 2024 and 2023, respectively. The Company recorded $0 and $88,846 of put premiums related to the above note issuances during the three months ended September 30, 2024 and 2023, respectively. The debt discounts are being amortized over the term of the debt and the put premiums are expensed on issuance of the debt with the liability released to additional paid in capital on conversion of the principal.

 

Amortization of all debt discounts for the three months ended September 30, 2024 and 2023 was $56,983 and $69,457, respectively.

 

The Company reclassified $9,336 and $34,838 in put premiums to additional paid in capital following conversions during the three months ended September 30, 2024 and 2023, respectively.

 

NOTE 7 – STOCKHOLDERS’ DEFICIT

 

Increase in Authorized Shares of Common Stock and Reverse Stock Split

 

On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its certificate of incorporation, as amended (the “Certificate of Incorporation”), which increased the Company’s authorized capital stock. Such certificate of amendment increased the number of authorized shares of common stock from 1,000,000,000 to 3,000,000,000 shares. The number of authorized shares of preferred stock remained at 1,500,005 shares, such that the total number of authorized shares of capital stock increased to 3,001,500,005 shares. Such certificate of amendment was filed and became effective on July 6, 2022.

 

On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its Certificate of Incorporation, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of common stock from 3,000,000,000 to 10,000,000,000 shares. The number of authorized shares of preferred stock remained at 1,500,005, such that the total number of shares of authorized capital stock increased to 10,001,500,005 shares. Such certificate of amendment was filed and became effective on November 4, 2022.

 

On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) Reverse Stock Split (the “Reverse Stock Split”), effective as of May 1, 2023. Proportional adjustments for the Reverse Stock Split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the condensed consolidated financial statements to reflect the Reverse Stock Split.

 

Preferred Stock

 

The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005, $0.01 par value per share. These preferred shares have no rights to dividends, profit sharing or liquidation preferences, subject to any such rights provided for such shares in any certificate of designation filed by the Company with the State of Delaware.

 

F-17
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Of the total preferred shares authorized, 500,000 had been designated as Series A Preferred Stock (“Series A Preferred Stock”), pursuant to the Certificate of Designation for the Series A Preferred Stock filed with the Secretary of State of the State of Delaware on December 9, 2014. James Nathanielsz, the Company’s Chief Executive Officer and Chief Financial Officer and a director, beneficially owned all of the outstanding shares of Series A Preferred Stock indirectly through North Horizon Pty Ltd., which entitled him, as a holder of Series A Preferred Stock, to vote on all matters submitted or required to be submitted to a vote of the Company’s stockholders, except election and removal of directors, and each share of Series A Preferred Stock entitled him to a total of 1 vote. North Horizon Pty Ltd. is a Nathanielsz Family Trust. Mr. Nathanielsz had voting and investment power over these shares.

 

On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No shares of Series A Preferred Stock are currently outstanding as they were redeemed by the Company in March 2023. There were no shares of Series A Preferred Stock issued and outstanding as of September 30, 2024 and June 30, 2024 for both periods.

 

Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $0.01 per share, of the Company (“Series B Preferred Stock”). Each holder of shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One share of Series B Preferred Stock is issued and outstanding as of September 30, 2024 and June 30, 2024. Mr. Nathanielsz, the Company’s Chief Executive Officer, directly beneficially owns such one share of Series B Preferred Stock.

 

No additional shares of Series A Preferred Stock or Series B Preferred Stock were issued during three months ended September 30, 2024 and fiscal year 2024.

 

Common Stock:

 

Shares issued for conversion of convertible debt

 

From July 1, 2024 through September 30, 2024, the Company issued an aggregate of 194,219,529 shares of its common stock at an average contractual conversion price of $0.0002 as a result of the conversion of principal of $44,925, interest of $7,053 and conversion fees $2,548 underlying certain outstanding convertible notes converted during such period.

 

Included in the above conversion during the three months ended September 30, 2024, were principal aggregate amount of convertible notes of $30,800, accrued interest of $2,212 and conversion fees of $798 containing bifurcated embedded conversion option derivatives were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $79,176, resulting in a loss on extinguishment at the time of conversion of $45,365 and $34,046 of derivative liability fair value was recorded as a gain on extinguishment at the time of conversion, resulting in a net loss of $11,319 which is included in gain (loss) on extinguishment of debt in the accompanying condensed consolidated statements of operations.

 

The Company reclassified $9,336 from put premium liabilities to additional paid in capital following conversions during the three months ended September 30, 2024.

 

The Company has 7,100,870,280 shares of its common stock reserved for future issuances based on lender reserve requirements pursuant to underlying financing agreements at September 30, 2024.

 

Shares issued for services

 

On August 12, 2024, the Company entered into a consulting agreement with two consultants to provide investor relation services from August 12, 2024 to October 12, 2024 for a total fee of $7,500 for each consultant. In August 2024, the Company issued an aggregate of 15,000,000 shares of common stock to the consultants related to this consulting agreement. Those shares were valued at approximately $0.001 per share or $15,000, being the closing price of the stock on the date of grant to such consultants. During the three months ended September 30, 2024, the Company recorded stock-based compensation of $7,500 and prepaid stock-based expense of $7,500 as of September 30, 2024.

 

Restricted Stock Units

 

Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 0.078 and 0.039 restricted stock unit to the Company’s Chief Executive Officer and Chief Scientific Officer, respectively. The total 0.117 restricted stock units are subject to vesting terms as defined in the employment agreements. The 0.117 restricted stock units were valued at the fair value of approximately $4,250,000 per unit or $497,240 based on the quoted trading price on the date of grant. There were $248,620 unrecognized restricted stock units expense as of September 30, 2024 and June 30, 2024. There are 0.06 unvested restricted stock units which are subject to various performance conditions which have not yet been met and such restricted stock units have not yet vested as of September 30, 2024 to which the $248,620 relates to.

 

F-18
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Stock Warrants:

 

The following table summarizes warrant activity for the three months ended September 30, 2024:

 

       Weighted 
   Number of   Average 
   Shares   Price Per Share 
Outstanding at June 30, 2024   15,003,396   $1.24 
Granted   -    - 
Exercised   -    - 
Forfeited   -    - 
Expired   -    - 
Outstanding at September 30, 2024   15,003,396*  $1.24 
           
Exercisable at September 30, 2024   15,003,378   $1.24 
Outstanding and Exercisable:          
           
Weighted average remaining contractual term   1.76      
Aggregate intrinsic value
  $-      

 

* The total warrants of 15,003,396 above which are exercisable into common stock consisted of the following:

 

   Number of Warrants   Exercisable 
Series A warrants   10    10 
Series B warrants   16    16 
Series C warrants   64    46 
Warrants with no class designation   15,003,306    15,003,306 
Total   15,003,396    15,003,378 

 

Stock Options:

 

A summary of the Company’s option activity during the three months ended September 30, 2024 is presented below:

 

       Weighted 
   Number of   Average Exercise 
   Shares   Price Per Share 
Outstanding at June 30, 2024   0.059   $4,533,000 
Granted   -    - 
Exercised   -    - 
Forfeited   -    - 
Expired   -    - 
Outstanding at September 30, 2024   0.059   $4,533,000 
           
Exercisable at September 30, 2024   0.059   $4,533,000 
Outstanding and Exercisable:          
           
Weighted average remaining contractual term   4.62      
Weighted average fair value of options granted during the period  $-      
Aggregate intrinsic value  $-      

 

On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 shares of the Company’s common stock for issuance under the 2019 Plan. Incentive awards authorized under the 2019 Plan include, but are not limited to, incentive stock options, non-qualified stock options, restricted stock awards and restricted stock units.

 

During the three months ended September 30, 2024 and 2023, the Company recognized stock-based compensation of $0 for both periods from vested stock options. There was $0 of unvested stock options expense as of September 30, 2024. No stock options were granted during the three months ended September 30, 2024.

 

F-19
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Proposed Reverse Stock Split (Unaudited)

 

On August 7, 2024, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company’s outstanding capital stock as of August 7, 2024 and the Company’s Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) (the “Reverse Stock Split”). Proportional adjustments for the Reverse Stock Split will be made to the Company’s outstanding stock options, warrants and equity incentive plans. The Company is awaiting the approval of Financial Industry Regulatory Authority (“FINRA”) for the market effectiveness of the Reverse Stock Split.

 

The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio.

 

Historical per share data – (Pre- Split basis) 

Three months
Ended

September 30, 2024

  

Three months

Ended

September 30, 2023

 
         
Net loss available to Common Stockholders  $354,310   $493,441 
Basic and diluted weighted average shares outstanding   590,937,498    10,989,681 
Basic and diluted net loss per share  $0.00   $0.04 

 

The table below reflects the reverse split of 1:60,000.

 

Historical per share data – (Post- Split basis) 

Three months
Ended

September 30, 2024

  

Three months

Ended

September 30, 2023

 
         
Net loss available to Common Stockholders  $354,310   $493,441 
Basic and diluted weighted average shares outstanding   9,849    183 
Basic and diluted net loss per share  $35.97   $2,696.40 

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

Legal Matters

 

From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

 

IRS Liability

 

As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest, such penalty and interest having been accrued and is included in the accrued expenses and other payable figure on the September 30, 2024 and June 30, 2024 consolidated balance sheets. The Company recorded the penalties for all three years during the year ended June 30, 2018. The Company is current on all subsequent filings.

 

F-20
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

 

Operating Agreements

 

In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2% of net revenues to the UK University. Additionally, the Company agreed to pay 5% of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts are owed under the agreement.

 

Collaboration Agreement

 

On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 Euros ($59,508 USD) in year one and a maximum of 40,000 Euros ($45,775 USD) in year two. Additionally, in exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2% of net revenues to the University.

 

On October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 Euros ($35,145 USD), which were paid in four installment payment of 5,000 Euros in November 2020, 5,000 Euros ($5,858) in March 2021, 10,000 Euros ($11,715) in December 2021 and 10,000 Euros ($11,715) in September 2022. Additionally, the University agreed to hire and train a doctoral student for this project and the Company agreed to pay the University 25,837 Euros ($30,268 USD). In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2% of net revenues to the University.

 

On July 27, 2022, the Company entered int